Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel, multifunctional biotherapeutics for difficult-to-treat diseases, will be present at:
1. BTIG Virtual Biotechnology Conference on August 6, where management will engage in virtual one-on-one meetings and a fireside chat at 4:00 pm ET.
2. Wedbush PacGrow Healthcare Conference on August 13-14 in New York, NY. Here, Zymeworks will participate in a panel discussion titled 'ADCs and Old Lace: Antibody Drug Conjugates' on August 14 from 8:45 – 9:25 am ET, as well as one-on-one meetings throughout the event.
These conferences provide Zymeworks with opportunities to showcase their progress and engage with investors in the biotechnology sector.
Zymeworks Inc. (Nasdaq: ZYME), una compagnia biotecnologica in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda, che si concentra sullo sviluppo di bioterapeutiche multifunzionali innovative per malattie difficili da trattare, sarà presente a:
1. BTIG Virtual Biotechnology Conference il 6 agosto, dove la direzione parteciperà a incontri virtuali individuali e a una chiacchierata informale alle 16:00 ET.
2. Wedbush PacGrow Healthcare Conference il 13-14 agosto a New York, NY. Qui, Zymeworks parteciperà a una tavola rotonda intitolata 'ADCs and Old Lace: Antibody Drug Conjugates' il 14 agosto dalle 8:45 alle 9:25 ET, oltre a incontri individuali durante l'evento.
Queste conferenze offrono a Zymeworks l'opportunità di mostrare i propri progressi e interagire con gli investitori nel settore biotecnologico.
Zymeworks Inc. (Nasdaq: ZYME), una empresa biotecnológica en fase clínica, ha anunciado su participación en dos próximas conferencias para inversores. La compañía, que se enfoca en desarrollar bioterapéuticas multifuncionales novedosas para enfermedades difíciles de tratar, estará presente en:
1. BTIG Virtual Biotechnology Conference el 6 de agosto, donde la dirección participará en reuniones virtuales uno a uno y en una charla informal a las 4:00 p.m. ET.
2. Wedbush PacGrow Healthcare Conference del 13 al 14 de agosto en Nueva York, NY. Aquí, Zymeworks participará en una discusión de panel titulada 'ADCs and Old Lace: Antibody Drug Conjugates' el 14 de agosto de 8:45 a 9:25 a.m. ET, así como en reuniones uno a uno durante el evento.
Estas conferencias brindan a Zymeworks oportunidades para mostrar su progreso e interactuar con inversores en el sector biotecnológico.
자이메웍스 주식회사 (Nasdaq: ZYME), 임상 단계의 생명공학 회사,가 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 난치병을 위한 혁신적인 다기능 생물 치료제를 개발하는 데 주력하는 이 회사는 다음 회의에 참석할 예정입니다:
1. BTIG 가상 생명공학 회의가 8월 6일 열리며, 여기서 경영진은 가상 일대일 회의와 오후 4시에 진행되는 대화에 참여할 것입니다.
2. Wedbush PacGrow 헬스케어 회의가 8월 13일부터 14일까지 뉴욕에서 열립니다. 자이메웍스는 8월 14일 오전 8시 45분부터 9시 25분까지 진행되는 'ADCs and Old Lace: 항체 약물 접합체'라는 제목의 패널 토론에 참여하며, 행사 전반에 걸쳐 일대일 회의도 진행합니다.
이 회의는 자이메웍스가 자신의 발전을 보여주고 생명공학 분야의 투자자와 소통할 수 있는 기회를 제공합니다.
Zymeworks Inc. (Nasdaq: ZYME), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise, qui se concentre sur le développement de biothérapeutiques novateurs et multifonctionnels pour des maladies difficiles à traiter, sera présente à :
1. BTIG Conférence Virtuelle de Biotechnologie le 6 août, où la direction participera à des réunions virtuelles en tête-à-tête et à une discussion informelle à 16h00 ET.
2. Conférence Wedbush PacGrow Healthcare les 13 et 14 août à New York, NY. Zymeworks participera ici à une discussion de panel intitulée 'ADCs and Old Lace: Antibody Drug Conjugates' le 14 août de 8h45 à 9h25 ET, ainsi qu'à des réunions en tête-à-tête tout au long de l'événement.
Ces conférences offrent à Zymeworks l'opportunité de présenter ses progrès et d'échanger avec des investisseurs du secteur biotechnologique.
Zymeworks Inc. (Nasdaq: ZYME), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen, das sich auf die Entwicklung neuartiger, multifunktionaler Biotherapeutika für schwer zu behandelnde Krankheiten konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. BTIG Virtuelle Biotechnologie-Konferenz am 6. August, wo das Management an virtuellen Eins-zu-eins-Meetings und einem informellen Gespräch um 16:00 Uhr ET teilnehmen wird.
2. Wedbush PacGrow Gesundheitskonferenz am 13. und 14. August in New York, NY. Hier wird Zymeworks an einer Podiumsdiskussion mit dem Titel 'ADCs and Old Lace: Antibody Drug Conjugates' am 14. August von 8:45 bis 9:25 Uhr ET teilnehmen sowie während der gesamten Veranstaltung Einzelgespräche führen.
Diese Konferenzen bieten Zymeworks die Möglichkeit, ihre Fortschritte zu präsentieren und mit Investoren im Biotechnologiesektor in Kontakt zu treten.
- None.
- None.
VANCOUVER, British Columbia, July 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
- BTIG Virtual Biotechnology Conference: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on Tuesday, August 6 at 4:00 pm Eastern Time (ET).
- Wedbush PacGrow Healthcare Conference: Zymeworks’ management will participate a panel discussion titled “ADCs and Old Lace: Antibody Drug Conjugates” taking place on August 14, between 8:45 – 9:25 am ET, and will participate in one-on-one meetings on August 13-14 in New York, NY.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
investors@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
ir@zymeworks.com
media@zymeworks.com
FAQ
What investor conferences will Zymeworks (ZYME) attend in August 2024?
What type of presentation will Zymeworks (ZYME) give at the BTIG Virtual Biotechnology Conference?
What panel will Zymeworks (ZYME) participate in at the Wedbush PacGrow Healthcare Conference?
Where will the Wedbush PacGrow Healthcare Conference be held for Zymeworks (ZYME)?
